JSC Lancet
Company
JSC Lancet develops one asset. Mostly antibody acting on EGFR.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 3
- Signals
Pipeline
1Binds EGFR and blocks signaling that promotes tumor cell growth and survival.
Stage not known, Antibody, EGFR, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals9
- Similar companies6